TIDMSNG
RNS Number : 7334P
Synairgen plc
21 October 2021
Press Release
Synairgen plc
('Synairgen' or the 'Company')
Grant of options
Southampton, UK - 21 October 2021: Synairgen plc (LSE: SNG), the
respiratory company developing SNG001, a formulation for inhalation
containing the broad-spectrum antiviral protein interferon beta
(IFN-beta) for the treatment of severe viral lung infections,
announces that on 20 October 2021 the Board of Synairgen granted
options ('Options') over 428,502 ordinary shares of one pence each
in the capital of the Company ('Ordinary Shares') at an exercise
price of one pence per Ordinary Share to employees of Synairgen
Research Limited, a wholly-owned subsidiary of the Company. The
Options represent in aggregate 0.21 per cent. of the Company's
issued share capital.
Following this grant, Synairgen has 8,463,223 options in issue,
representing 4.20 per cent. of the Company's issued share
capital.
Included in the number of Options granted as above, the
following Options were issued to Persons Discharging Managerial
Responsibilities ('PDMR'), who have no other holdings of ordinary
shares or options in the Company:
PDMR Options Issued
Brooke Clarke 113,636
---------------
Richard Francis 113,636
---------------
Gareth Walters 120,779
---------------
The Options are issued under the Company's Long Term Incentive
Plans and are exercisable up to 19 October 2031, subject to the
achievement of appropriate performance criteria.
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Brooke Clarke, Head of Communications
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate
Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and
Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MK Strategies, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516 606 6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery, development and commercialisation. The Company's primary
focus is developing SNG001 (inhaled interferon beta) for the
treatment of COVID-19 as potentially the first host-targeted,
broad-spectrum antiviral treatment delivered directly into the
lungs. Granted Fast Track status from the US Food and Drug
Administration (FDA) and deemed an Urgent Public Health study by
the UK's National Institute for Health Research (NIHR), Synairgen's
Phase III clinical programme is currently evaluating nebulised
SNG001 in patients across 17 countries. In a Phase II trial in
hospitalised COVID-19 patients, SNG001 demonstrated a greater than
two-fold chance of recovery to 'no limitation of activities' versus
placebo.(1)
Founded by University of Southampton Professors Sir Stephen
Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com.
References
1 -
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Brooke Clarke
2. Reason for notification
a) Position / status Head of Communications
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 113,636 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 20 October 2021
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Richard Francis
2. Reason for notification
a) Position / status Head of CMC
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 113,636 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 20 October 2021
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Gareth Walters
2. Reason for notification
a) Position / status Chief Regulatory Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 120,779 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 20 October 2021
f) Place of the transaction Outside a trading venue
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHMMBRTMTTTBFB
(END) Dow Jones Newswires
October 21, 2021 02:00 ET (06:00 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024